Inventor · disambiguated record
Sohye Kang
Also filed as: KANG SOHYE
8 granted patents·1 pending application·1 citations·filing 2011–2024
74Inventor score
Top patents by PatentIndex Score
9 records- 0180US10655156B2Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteinsAMGEN INC·Filed 2019·Granted May 19, 2020·1 cites·21 claims
- 0271US2025297001A1Antibody Compositions Comprising Fc Mutations and Site-Specific Conjugation Properties for Use in Treating Cancer, Immunological Disorders, and Methods ThereofTAE LIFE SCIENCES LLC·Filed 2024·Application pending·0 cites
- 0368US10907186B2Overexpression of n-glycosylation pathway regulators to modulate glycosylation of recombinant proteinsAMGEN INC·Filed 2020·Granted Feb 2, 2021·0 cites·9 claims
- 0466US10227627B2Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteinsAMGEN INC·Filed 2018·Granted Mar 12, 2019·0 cites·21 claims
- 0565US11254963B2Increasing ornithine accumulation to increase high mannose glycoform content of recombinant proteinsAMGEN INC·Filed 2019·Granted Feb 22, 2022·0 cites·16 claims
- 0658US10513723B2Decreasing ornithine production to decrease high mannose glycoform content of recombinant proteinsAMGEN INC·Filed 2014·Granted Dec 24, 2019·0 cites·17 claims
- 0755US12202893B2Antibody compositions comprising Fc mutations and site-specific conjugation properties for use in treating cancer, immunological disorders, and methods thereofTAE Life Sciences·Filed 2020·Granted Jan 21, 2025·0 cites·33 claims
- 0850US10106829B2Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteinsAMGEN INC·Filed 2014·Granted Oct 23, 2018·0 cites·12 claims
- 0937US9012178B2Dipeptides to enhance yield and viability from cell culturesKANG SOHYE·Filed 2011·Granted Apr 21, 2015·0 cites·24 claims
Join the waitlist — get patent alerts
Get an alert when Sohye Kang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →